Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
Abstract Targeting checkpoint inhibitors using monoclonal antibodies results in significantly better outcome of cancer patients compared to conventional chemotherapy. However, the current companion diagnostics to predict response is so far suboptimal, since they base on more or less reliable immunoh...
Main Authors: | Sebastian Marwitz, Swetlana Scheufele, Sven Perner, Martin Reck, Ole Ammerpohl, Torsten Goldmann |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | Clinical Epigenetics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13148-017-0354-2 |
Similar Items
-
Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01) -
NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
by: Leona Raskova Kafkova, et al.
Published: (2024-02-01) -
Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Chengdi Wang, et al.
Published: (2019-07-01) -
Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
by: Joe Yeong, et al.
Published: (2019-02-01) -
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
by: Reid P. Bissonnette, et al.
Published: (2021-08-01)